ACON Stock — Aclarion Inc

Aclarion Inc (ACON)

Updated October 16, 2026.

ACON is a Stock. Its deepest 1-year drawdown was 78.7%.

Aclarion is a healthcare technology company that develops magnetic resonance spectroscopy-based diagnostic tools for analyzing spinal disc degeneration. Its flagship product, NOCISCAN, uses MRS imaging combined with proprietary software to non-invasively assess intervertebral discs and generate degenerative pain biomarkers, along with related post-processing software and imaging data transfer platforms. The company does not currently have a known distribution history.

ACON performance

Returns are updating. ACON's total return appears here after the next nightly update.

Its deepest 1-year drawdown was 78.7%.

ACON key facts

Asset type

Stock

Asset class

Equity

Inception date

04/22/2022

Distribution frequency

None

Last close

$1.85 (as of 2026-10-16)

Market cap

$5,332,386

Average volume

11262.0

Beta

1.206

Payout ratio

0.0%

EPS

$-7.38

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

ACON risks and drawbacks

The deepest 1-year drawdown on record here is 78.7%.

Who may consider ACON — and who may not

It is a weaker fit for investors who need monthly cash flow (ACON does not currently distribute). This is educational context, not a recommendation to buy or sell.

More on ACON

• All tickers starting with A

Tagged: Healthcare.

Frequently asked questions